HyBryte demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment course PRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ...
JACKSONVILLE, Fla., March 27, 2026 /PRNewswire/ -- BionicM USA LLC and Brooks Rehabilitation have announced a collaborative clinical research study, titled Adaptive Mobility Technology: A Comparative ...
Correspondence to Dr Parco M Siu, The University of Hong Kong, Hong Kong, 999077, Hong Kong; pmsiu{at}hku.hk Data sources Embase, MEDLINE, PsycINFO, Cochrane Library, Web of Science, Scopus and ...
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health ...
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study We divided the borrowing ...
Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced ...
RAAS inhibitors outperform CCBs in paediatric CKD, lowering kidney failure risk. Discover how this real-world study could shape first-line treatment. Read more.
The comparative effectiveness of glucose-lowering medications for use with metformin to maintain target glycated hemoglobin levels in persons with type 2 diabetes is uncertain. In this trial involving ...
Drugs like semaglutide, the active ingredient of Ozempic and Wegovy, are more effective in treating type 2 diabetes than conventional treatments, a comprehensive new comparative study finds. About one ...
Prestige Biopharma today announced positive topline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results